Is tirzepatide stronger than semaglutide?

In the SURPASS-2 trial in type 2 diabetes, tirzepatide produced larger average reductions in HbA1c and body weight than semaglutide 1 mg weekly across its tested dose range. Direct comparisons at each compound's maximum approved weight-management dose are ongoing. The mechanism is different: tirzepatide activates two incretin receptors in one molecule, while semaglutide activates only GLP-1.

What is the difference between Ozempic and Wegovy?

Both are brand names for semaglutide from Novo Nordisk, but they are approved at different dose ranges for different indications. Ozempic is approved for type 2 diabetes with a maximum dose of 2 mg weekly in most jurisdictions. Wegovy is approved for chronic weight management with a maximum dose of 2.4 mg weekly. The active molecule is the same.

Is retatrutide approved?

No. As of late 2024, retatrutide remained an investigational compound in phase 3 trials (the TRIUMPH program). It has not been approved by the FDA or any other regulatory agency. Phase 2 data has been published in the New England Journal of Medicine but is not a substitute for phase 3 evidence and formal regulatory review.

Do GLP-1 agonists cause muscle loss?

Any large weight loss tends to include a proportion of lean tissue alongside fat. Published trial analyses of semaglutide and tirzepatide include body composition data suggesting that a substantial portion of weight loss is fat mass, but lean mass does also decrease. The clinical significance and mitigation strategies (resistance training, protein intake) are active research questions.

GLP-1 Receptor Agonists: What the Research Shows

Published: April 10, 2026•Updated: April 10, 2026

Research use only. This article discusses compounds that include approved medications, investigational drugs, and research peptides. Material sold for research is not cleared for human administration and is not a substitute for medical advice.

GLP-1 receptor agonists have become one of the most talked-about drug classes of the past decade. This article walks through what they are, how they work, and what the peer-reviewed clinical research actually shows. It covers the first-generation single agonists like semaglutide, the dual agonist tirzepatide, and the investigational triple agonist retatrutide.

What GLP-1 actually is

Glucagon-like peptide-1 (GLP-1) is a hormone secreted by L cells in the small intestine in response to food. It plays several roles in normal physiology: it triggers glucose-dependent insulin release from the pancreas, suppresses glucagon, slows the rate at which the stomach empties into the intestine, and signals satiety through receptors in the brain.

Native GLP-1 has a half-life of only about two minutes because the enzyme DPP-4 rapidly cuts it into inactive fragments. That short half-life was the central problem researchers needed to solve before GLP-1 could become a practical therapeutic. The solution was to engineer analogs that resist DPP-4 and remain in circulation long enough to work.

The three generations of agonists

The GLP-1 receptor agonist class has evolved through three broad generations, each building on what came before.

Single agonists (GLP-1 only)

Exenatide was the first, approved in 2005, followed by liraglutide (Victoza) in 2010. Semaglutide (Ozempic/Wegovy) represents the current state of the art in this group, with a weekly dosing schedule and strong cardiovascular and weight-management data.

Dual agonists (GLP-1 + GIP)

Tirzepatide (Mounjaro/Zepbound), approved in 2022, activates both the GLP-1 and GIP receptors in a single molecule. In head-to-head trials against semaglutide in type 2 diabetes (SURPASS-2), tirzepatide produced larger reductions in HbA1c and body weight across its tested dose range.

Triple agonists (GLP-1 + GIP + glucagon)

Retatrutide, still investigational as of late 2024, adds glucagon receptor activity to the mix. Phase 2 data published in NEJM in 2023 reported average body weight reductions around 24 percent at 48 weeks at the highest dose tested. Phase 3 TRIUMPH trials are underway.

How the mechanism is thought to work

The weight-related effects of GLP-1 receptor agonists appear to come from several coordinated actions, not a single mechanism. The picture researchers paint from clinical and preclinical data goes something like this:

•Receptors in the hindbrain and hypothalamus respond to the drug by dampening hunger signals, which reduces caloric intake
•Slowed gastric emptying prolongs the feeling of fullness after a meal and flattens post-meal glucose spikes
•Glucose-dependent insulin secretion improves control without the hypoglycemia risk that comes with insulin itself
•Reduced glucagon secretion after meals lowers hepatic glucose output
•In the case of tirzepatide, added GIP receptor activity may contribute further effects on insulin response and adipose tissue biology
•In the case of retatrutide, added glucagon receptor activity is proposed to increase energy expenditure and hepatic fat turnover

What the clinical trials established

The evidence base for this class is unusually large. Each major compound has been tested in multiple randomized controlled trials, often with tens of thousands of participants in aggregate.

Semaglutide

The STEP 1 trial in obesity, published in NEJM in 2021, reported an average body weight reduction of about 14.9 percent at 68 weeks on semaglutide 2.4 mg weekly, compared with 2.4 percent on placebo. The SUSTAIN-6 trial in type 2 diabetes showed reduced major adverse cardiovascular events in high-risk patients. The SELECT trial, published in 2023, extended the cardiovascular findings to people with overweight or obesity without diabetes.

Tirzepatide

The SURMOUNT-1 trial, published in NEJM in 2022, reported body weight reductions ranging from roughly 15 to 21 percent at 72 weeks across tirzepatide dose groups. SURPASS trials in type 2 diabetes established non-inferiority or superiority against insulin and semaglutide in various comparisons.

Retatrutide

Phase 2 data published in NEJM in 2023 reported body weight reductions around 24 percent at 48 weeks at the highest tested dose. Phase 3 results from the TRIUMPH program were still being generated as of late 2024, and no regulatory approval had been granted.

Safety, side effects, and open questions

The most commonly reported adverse events across the class are gastrointestinal: nausea, vomiting, diarrhea, and constipation, most prominent during dose escalation. The prescribing information for approved drugs in this class also includes warnings for pancreatitis, gallbladder disease, and acute kidney injury in the setting of severe dehydration.

A boxed warning on FDA labels for this class addresses thyroid C-cell tumors seen in rodent studies. The clinical significance in humans is uncertain, and the label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or MEN 2.

Open questions that clinical researchers continue to investigate include the durability of benefit after discontinuation, effects on lean body mass during rapid weight loss, long-term cardiovascular and metabolic outcomes, use in specific subpopulations, and the comparative effectiveness of dual and triple agonists against simpler GLP-1 agonists at matched doses.

The research chemical market

Outside regulated prescription channels, peptides in this class are also sold as research chemicals through suppliers that market them for laboratory use. These products are not FDA cleared, have no approved prescribing information, and cannot be verified for identity and purity without independent analytical testing. Content on this site that references research chemical sources is informational and is not a substitute for a conversation with a physician.